Skip to main content

Jim Cramer Says He's Skeptical About a Vaccine Rollout

Publish date:
Video Rating:
Video Duration:

We've got more positive vaccine news on Monday, Nov. 23. 

AstraZeneca came out with data from its vaccine trial.

According to a press release, AstraZeneca and the University of Oxford's vaccine candidate was found in a large trial to have "showed vaccine efficacy of 90% when [the candidate] was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens resulted in an average efficacy of 70%."

WATCH: Everything Jim Cramer Is Watching in Markets Monday

Latest Videos From TheStreet and Jim Cramer:

Related Videos